Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 2
2018 4
2019 2
2020 1
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.
Flaherty KR, Fell CD, Huggins JT, Nunes H, Sussman R, Valenzuela C, Petzinger U, Stauffer JL, Gilberg F, Bengus M, Wijsenbeek M. Flaherty KR, et al. Among authors: bengus m. Eur Respir J. 2018 Aug 2;52(2):1800230. doi: 10.1183/13993003.00230-2018. Print 2018 Aug. Eur Respir J. 2018. PMID: 29946005 Free PMC article. Clinical Trial.
Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J, Nathan SD, Wuyts WA, Mogulkoc Bishop N, Bouros DE, Antoniou K, Guiot J, Kramer MR, Kirchgaessler KU, Bengus M, Gilberg F, Perjesi A, Harari S, Wells AU. Behr J, et al. Among authors: bengus m. Lancet Respir Med. 2021 Jan;9(1):85-95. doi: 10.1016/S2213-2600(20)30356-8. Epub 2020 Aug 18. Lancet Respir Med. 2021. PMID: 32822614 Clinical Trial.
Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials.
Seshasai SR, Bennett RL, Petrie JR, Bengus M, Ekman S, Dixon M, Herz M, Buse JB, Ray KK. Seshasai SR, et al. Among authors: bengus m. Diabetes Obes Metab. 2015 May;17(5):505-10. doi: 10.1111/dom.12448. Epub 2015 Mar 4. Diabetes Obes Metab. 2015. PMID: 25656522 Review.
Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design.
Behr J, Nathan SD, Harari S, Wuyts W, Kirchgaessler KU, Bengus M, Gilberg F, Wells AU. Behr J, et al. Among authors: bengus m. Respir Med. 2018 May;138:13-20. doi: 10.1016/j.rmed.2018.03.019. Epub 2018 Mar 16. Respir Med. 2018. PMID: 29724385 Free article.
Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study.
Wijsenbeek MS, Bendstrup E, Valenzuela C, Henry MT, Moor CC, Jouneau S, Fois AG, Moran-Mendoza O, Anees S, Mirt M, Bengus M, Gilberg F, Kirchgaessler KU, Vancheri C. Wijsenbeek MS, et al. Among authors: bengus m. Adv Ther. 2021 Jun 11:1-17. doi: 10.1007/s12325-021-01790-y. Online ahead of print. Adv Ther. 2021. PMID: 34117601 Free PMC article.